ERCC1基因表达与晚期非小细胞肺癌铂类化疗方案疗效的前瞻性研究  

The prospective study of relationship between expression of ERCC1 and effect of platinum-based chemotherapy in patients with advanced NSCLC

作　　者：刘晓燕[1] 邹青峰[1] 陈文晟[1] 马磊[1] 李志彪[1] 

机构地区：[1]广州医学院附属肿瘤医院内三科,广东广州510095

出　　处：《中国当代医药》2013年第16期3-4,7,共3页China Modern Medicine

基　　金：广东省广州市卫生局资助项目(编号:201102A213009)

摘　　要：目的探讨核苷酸切除修复交叉互补组基因1(ERCC1)基因表达与晚期非小细胞肺癌铂类化疗方案的疗效。方法入组40例晚期非小细胞肺癌患者,实验组选取化疗前采用分支DNA-液相芯片技术检测确定为ERCC1 mRNA低表达的患者,对照组为同期住院的非ERCC1 mRNA低表达患者,每组各20例。每组患者行至少4个周期的含铂的化疗方案治疗,评价两组的化疗反应率、疾病进展时间。结果实验组患者的化疗有效率、疾病进展时间分别为85.0%、11.6个月;对照组的化疗有效率、疾病进展时间分别为30.0%、7.9个月,差异有统计学意义。结论ERCC1基因表达可作为预测晚期非小细胞肺癌对含铂化疗方案的敏感性的指标。Objective To investigate the effect between genetic polymorphisms of ERCC1 and survival of patients with advanced non-small cell lung cancer （NSCLC） treated with platinum based chemotherapy. Methods A total of 40 patients with advanced NSCLC were routinely treated by cisplatin or carboplatin-based chemotherapy, the experimental group selection of chemotherapy before the branch DNA-liquid chip technology testing identified as ERCC1 low mRNA expression of patients, the control group for the same period of hospitalization of ERCC1 mRNA expression in patients with low, each group in 20 cases. Each group patients received four cycles of platinum-based chemotherapy. The response rate（RR） and the time to progression （TTP） were evaluated of the two groups. Results The RR and TTP were 85.0% and 11.6 months in the experimental group, those were 30.0% and 7.9 months in the control group, respectively. The difference between the two groups was significant. Conclusion Polymorphisms of ERCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy, which might be the predictive markers for overall survival.

关 键 词：非小细胞肺癌 分支DNA-液相芯片技术 核苷酸切除修复交叉互补组基因1 前瞻性研究 

分 类 号：R734.2[医药卫生—肿瘤]